196 related articles for article (PubMed ID: 27844282)
1. Morphological Changes in a Severe Model of Parkinson's Disease and Its Suitability to Test the Therapeutic Effects of Microencapsulated Neurotrophic Factors.
Requejo C; Ruiz-Ortega JA; Bengoetxea H; García-Blanco A; Herrán E; Aristieta A; Igartua M; Pedraz JL; Ugedo L; Hernández RM; Lafuente JV
Mol Neurobiol; 2017 Dec; 54(10):7722-7735. PubMed ID: 27844282
[TBL] [Abstract][Full Text] [Related]
2. Topographical Distribution of Morphological Changes in a Partial Model of Parkinson's Disease--Effects of Nanoencapsulated Neurotrophic Factors Administration.
Requejo C; Ruiz-Ortega JA; Bengoetxea H; Garcia-Blanco A; Herrán E; Aristieta A; Igartua M; Ugedo L; Pedraz JL; Hernández RM; Lafuente JV
Mol Neurobiol; 2015 Oct; 52(2):846-58. PubMed ID: 26041662
[TBL] [Abstract][Full Text] [Related]
3. Nanoformulation: A Useful Therapeutic Strategy for Improving Neuroprotection and the Neurorestorative Potential in Experimental Models of Parkinson's Disease.
Lafuente JV; Requejo C; Carrasco A; Bengoetxea H
Int Rev Neurobiol; 2017; 137():99-122. PubMed ID: 29132545
[TBL] [Abstract][Full Text] [Related]
4. Neurotrophic and neuroprotective efficacy of intranasal GDNF in a rat model of Parkinson's disease.
Migliore MM; Ortiz R; Dye S; Campbell RB; Amiji MM; Waszczak BL
Neuroscience; 2014 Aug; 274():11-23. PubMed ID: 24845869
[TBL] [Abstract][Full Text] [Related]
5. Comparative study of the neurotrophic effects elicited by VEGF-B and GDNF in preclinical in vivo models of Parkinson's disease.
Yue X; Hariri DJ; Caballero B; Zhang S; Bartlett MJ; Kaut O; Mount DW; Wüllner U; Sherman SJ; Falk T
Neuroscience; 2014 Jan; 258():385-400. PubMed ID: 24291725
[TBL] [Abstract][Full Text] [Related]
6. Evidence for an Additive Neurorestorative Effect of Simultaneously Administered CDNF and GDNF in Hemiparkinsonian Rats: Implications for Different Mechanism of Action.
Voutilainen MH; De Lorenzo F; Stepanova P; Bäck S; Yu LY; Lindholm P; Pörsti E; Saarma M; Männistö PT; Tuominen RK
eNeuro; 2017; 4(1):. PubMed ID: 28303260
[TBL] [Abstract][Full Text] [Related]
7. Intranasal Administration of GDNF Protects Against Neural Apoptosis in a Rat Model of Parkinson's Disease Through PI3K/Akt/GSK3β Pathway.
Yue P; Gao L; Wang X; Ding X; Teng J
Neurochem Res; 2017 May; 42(5):1366-1374. PubMed ID: 28247332
[TBL] [Abstract][Full Text] [Related]
8. 1,25-Dihydroxyvitamin D3 administration to 6-hydroxydopamine-lesioned rats increases glial cell line-derived neurotrophic factor and partially restores tyrosine hydroxylase expression in substantia nigra and striatum.
Sanchez B; Relova JL; Gallego R; Ben-Batalla I; Perez-Fernandez R
J Neurosci Res; 2009 Feb; 87(3):723-32. PubMed ID: 18816795
[TBL] [Abstract][Full Text] [Related]
9. Intracerebral administration of ultrasound-induced dissolution of lipid-coated GDNF microbubbles provides neuroprotection in a rat model of Parkinson's disease.
Wang X; Cui G; Yang X; Zhang Z; Shi H; Zu J; Hua F; Shen X
Brain Res Bull; 2014 Apr; 103():60-5. PubMed ID: 24583079
[TBL] [Abstract][Full Text] [Related]
10. Increased antiparkinson efficacy of the combined administration of VEGF- and GDNF-loaded nanospheres in a partial lesion model of Parkinson's disease.
Herrán E; Requejo C; Ruiz-Ortega JA; Aristieta A; Igartua M; Bengoetxea H; Ugedo L; Pedraz JL; Lafuente JV; Hernández RM
Int J Nanomedicine; 2014; 9():2677-87. PubMed ID: 24920904
[TBL] [Abstract][Full Text] [Related]
11. GDNF reduces drug-induced rotational behavior after medial forebrain bundle transection by a mechanism not involving striatal dopamine.
Tseng JL; Baetge EE; Zurn AD; Aebischer P
J Neurosci; 1997 Jan; 17(1):325-33. PubMed ID: 8987758
[TBL] [Abstract][Full Text] [Related]
12. In vivo administration of VEGF- and GDNF-releasing biodegradable polymeric microspheres in a severe lesion model of Parkinson's disease.
Herrán E; Ruiz-Ortega JÁ; Aristieta A; Igartua M; Requejo C; Lafuente JV; Ugedo L; Pedraz JL; Hernández RM
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):1183-90. PubMed ID: 23639739
[TBL] [Abstract][Full Text] [Related]
13. Mesencephalic astrocyte-derived neurotrophic factor is neurorestorative in rat model of Parkinson's disease.
Voutilainen MH; Bäck S; Pörsti E; Toppinen L; Lindgren L; Lindholm P; Peränen J; Saarma M; Tuominen RK
J Neurosci; 2009 Jul; 29(30):9651-9. PubMed ID: 19641128
[TBL] [Abstract][Full Text] [Related]
14. Rosiglitazone, a PPAR-γ agonist, protects against striatal dopaminergic neurodegeneration induced by 6-OHDA lesions in the substantia nigra of rats.
Lee EY; Lee JE; Park JH; Shin IC; Koh HC
Toxicol Lett; 2012 Sep; 213(3):332-44. PubMed ID: 22842585
[TBL] [Abstract][Full Text] [Related]
15. Sequential administration of GDNF into the substantia nigra and striatum promotes dopamine neuron survival and axonal sprouting but not striatal reinnervation or functional recovery in the partial 6-OHDA lesion model.
Rosenblad C; Kirik D; Björklund A
Exp Neurol; 2000 Feb; 161(2):503-16. PubMed ID: 10686072
[TBL] [Abstract][Full Text] [Related]
16. Delayed gene therapy of glial cell line-derived neurotrophic factor is efficacious in a rat model of Parkinson's disease.
Zheng JS; Tang LL; Zheng SS; Zhan RY; Zhou YQ; Goudreau J; Kaufman D; Chen AF
Brain Res Mol Brain Res; 2005 Mar; 134(1):155-61. PubMed ID: 15790539
[TBL] [Abstract][Full Text] [Related]
17. Effect of glial cell line-derived neurotrophic factor (GDNF) co-transplantation with fetal ventral mesencephalic cells (VMC) on functional restoration in 6-hydroxydopamine (6-OHDA) lesioned rat model of Parkinson's disease: neurobehavioral, neurochemical and immunohistochemical studies.
Chaturvedi RK; Agrawal AK; Seth K; Shukla S; Chauhan S; Shukla Y; Sinha C; Seth PK
Int J Dev Neurosci; 2003 Nov; 21(7):391-400. PubMed ID: 14599485
[TBL] [Abstract][Full Text] [Related]
18. Chronic infusion of CDNF prevents 6-OHDA-induced deficits in a rat model of Parkinson's disease.
Voutilainen MH; Bäck S; Peränen J; Lindholm P; Raasmaja A; Männistö PT; Saarma M; Tuominen RK
Exp Neurol; 2011 Mar; 228(1):99-108. PubMed ID: 21185834
[TBL] [Abstract][Full Text] [Related]
19. Protection of dopaminergic nigrostriatal afferents by GDNF delivered by microspheres in a rodent model of Parkinson's disease.
Gouhier C; Chalon S; Aubert-Pouessel A; Venier-Julienne MC; Jollivet C; Benoit JP; Guilloteau D
Synapse; 2002 Jun; 44(3):124-31. PubMed ID: 11954043
[TBL] [Abstract][Full Text] [Related]
20. Brain delivery of microencapsulated GDNF induces functional and structural recovery in parkinsonian monkeys.
Garbayo E; Ansorena E; Lana H; Carmona-Abellan MD; Marcilla I; Lanciego JL; Luquin MR; Blanco-Prieto MJ
Biomaterials; 2016 Dec; 110():11-23. PubMed ID: 27697668
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]